[Mexican National Consensus on Assisted Reproduction Treatment].

BACKGROUND It is estimated that 15% of couples living in industrialized countries are infertile, ie have failed to conceive, reproductive age, after 12 months ormore of regular intercourse without contraception. During the past decade has increased the demand for fertility treatments because they believe are moreeffective now. OBJECTIVE To unify the therapeutic approach and service to patients and set a precedent for a Mexican Official Standard respect and support for the legislation of these procedures. METHOD Consensus by technical experts group panel with the participation of 34 national centers accredited for use in assisted reproduction. He organized seven workshops with the following themes: 1) selection of patients for assisted reproduction treatment, 2) schemes controlled ovarian stimulation for assisted reproduction techniques of high complexity, 3) preparation and egg retrieval technique, 4) transferembryo; 5) luteal phase supplementation; 6) indications and techniques of cryopreservation and 7) informed consent. Each table had a coordinator who wrote and presented the findings to the full, it made a number of observations until they reached unanimity of criteria, which are reflected in this document. RESULTS Patient selection for assisted reproduction techniques is the first step of the process. Proper selection lead to success, in the same way that a bad pick up for failure. In the case of egg donation the most important recommendation is that only one to two embryos transferred in order to reduce multiple pregnancy rates and maintaining high pregnancy rates.

[1]  N. Macklon,et al.  Peri-implantation glucocorticoid administration for assisted reproductive technology cycles. , 2012, The Cochrane database of systematic reviews.

[2]  E. Kolibianakis,et al.  Increased live birth rates with GnRH agonist addition for luteal support in ICSI/IVF cycles: a systematic review and meta-analysis. , 2011, Human reproduction update.

[3]  S. Muasher,et al.  Mild/minimal stimulation for in vitro fertilization: an old idea that needs to be revisited. , 2011, Fertility and Sterility.

[4]  H. Tournaye,et al.  A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin-releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept study. , 2011, Fertility and sterility.

[5]  M. Eijkemans,et al.  Clinical outcomes in relation to the daily dose of recombinant follicle-stimulating hormone for ovarian stimulation in in vitro fertilization in presumed normal responders younger than 39 years: a meta-analysis. , 2011, Human reproduction update.

[6]  S. Silber,et al.  Minimal ovarian stimulation (mini-IVF) for IVF utilizing vitrification and cryopreserved embryo transfer. , 2010, Reproductive biomedicine online.

[7]  P. Humaidan,et al.  1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. , 2010, Fertility and sterility.

[8]  B. Urman,et al.  Effect of energy expenditure and physical activity on the outcomes of assisted reproduction treatment. , 2010, Reproductive biomedicine online.

[9]  L. Nardo,et al.  The use of estradiol for luteal phase support in in vitro fertilization/intracytoplasmic sperm injection cycles: a systematic review and meta-analysis. , 2008, Fertility and sterility.

[10]  N. Macklon,et al.  Does glucocorticoid therapy in the peri-implantation period have an impact on IVF outcomes? , 2008, Current opinion in obstetrics & gynecology.

[11]  J. Nulsen,et al.  The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. , 2008, Fertility and sterility.

[12]  R. Frydman,et al.  The ISMAAR proposal on terminology for ovarian stimulation for IVF. , 2007, Human reproduction.

[13]  E. Kolibianakis,et al.  Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? A systematic review and meta-analysis. , 2007, Human reproduction update.

[14]  C. Simón,et al.  Dopamine Agonist Cabergoline Reduces Hemoconcentration and Ascites in Hyperstimulated Women Undergoing Assisted Reproduction , 2007 .

[15]  N. Amso,et al.  Embryo freezing for preventing ovarian hyperstimulation syndrome. , 2007, The Cochrane database of systematic reviews.

[16]  O. Kato,et al.  Minimal ovarian stimulation with clomiphene citrate: a large-scale retrospective study. , 2007, Reproductive biomedicine online.

[17]  J. Tesarik,et al.  Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles. , 2006, Human reproduction.

[18]  J. Donnez,et al.  GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study. , 2006, Human reproduction.

[19]  M. Huleihel,et al.  Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. , 2006, Human reproduction.

[20]  V. Alam,et al.  Predictive factors and a corresponding treatment algorithm for controlled ovarian stimulation in patients treated with recombinant human follicle stimulating hormone (follitropin alfa) during assisted reproduction technology (ART) procedures. An analysis of 1378 patients , 2006, Current medical research and opinion.

[21]  G. Serour,et al.  Soft versus firm embryo transfer catheters for assisted reproduction: a systematic review and meta-analysis. , 2005, Human reproduction.

[22]  S. Oehninger,et al.  Controlled ovarian hyperstimulation protocols for in vitro fertilization: two decades of experience after the birth of Elizabeth Carr. , 2005, Fertility and sterility.

[23]  R. Orvieto,et al.  Immediate ambulation after embryo transfer: a prospective study. , 2005, Fertility and sterility.

[24]  R. Will,et al.  Creutzfeldt-Jakob disease and urinary gonadotrophins. , 2004, Human reproduction.

[25]  J. Tesarik,et al.  Enhancement of embryo developmental potential by a single administration of GnRH agonist at the time of implantation. , 2004, Human reproduction.

[26]  M. Eijkemans,et al.  Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with rec , 2003, The Journal of clinical endocrinology and metabolism.

[27]  Yu-Hung Lin,et al.  Ovarian stimulation by clomiphene citrate and hMG in combination with cetrorelix acetate for ICSI cycles. , 2003, Human reproduction.

[28]  A. Atwood,et al.  Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. , 2002, Human reproduction.

[29]  D. Seifer,et al.  Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. , 2002, Fertility and sterility.

[30]  P. Devroey,et al.  Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist Cetrorelix. , 2001, Human reproduction.

[31]  S. Oehninger,et al.  Impact of different clinical variables on pregnancy outcome following embryo cryopreservation , 2000, Molecular and Cellular Endocrinology.

[32]  M. Bahçeci,et al.  Addition of GnRH antagonist in cycles of poor responders undergoing IVF. , 2000, Human reproduction.

[33]  J. Hill,et al.  Will GnRH antagonists provide new hope for patients considered 'difficult responders' to GnRH agonist protocols? , 1999, Human reproduction.

[34]  N. Gleicher,et al.  A rational approach to the management of low responders in in-vitro fertilization. , 1999, Human reproduction.

[35]  J. Donnez,et al.  Outcome of in-vitro fertilization through natural cycles in poor responders. , 1999, Human reproduction.

[36]  J. Stanger,et al.  Ultrasound tracking of the movement of embryo-associated air bubbles on standing after transfer. , 1998, Human reproduction.

[37]  S. Oehninger,et al.  Cessation of gonadotropin-releasing hormone agonist therapy combined with high-dose gonadotropin stimulation yields favorable pregnancy results in low responders. , 1998, Fertility and sterility.

[38]  B. Fauser,et al.  Manipulation of human ovarian function: physiological concepts and clinical consequences. , 1997, Endocrine reviews.

[39]  H. Martikainen,et al.  Pretreatment transvaginal ultrasound examination predicts ovarian responsiveness to gonadotrophins in in-vitro fertilization. , 1997, Human reproduction.

[40]  G. Lambert-Messerlian,et al.  Day 3 serum inhibin-B is predictive of assisted reproductive technologies outcome. , 1997, Fertility and sterility.

[41]  S. Campbell,et al.  Relationship of Ovarian Stromal Blood Flow at the Baseline Ultrasound Scan to Subsequent Follicular Response in an In Vitro Fertilization Program , 1996, Obstetrics and gynecology.

[42]  P. Kroboth,et al.  Oral Administration of Micronized Progesterone: A Review and More Experience , 1996, Pharmacotherapy.

[43]  E. Atkinson,et al.  Minimal stimulation achieves pregnancy rates comparable to human menopausal gonadotropins in the treatment of infertility. , 1996, Fertility and sterility.

[44]  B. V. Van Voorhis,et al.  Ovarian volume: a novel outcome predictor for assisted reproduction. , 1995, Fertility and sterility.

[45]  D. Navot,et al.  Enhancement of ovarian responsiveness with microdoses of gonadotropin-releasing hormone agonist during ovulation induction for in vitro fertilization. , 1994, Fertility and sterility.

[46]  M. Milad,et al.  A novel ovarian stimulation protocol for use with the assisted reproductive technologies. , 1993, Fertility and sterility.

[47]  N. Laufer,et al.  Ovarian hyperstimulation syndrome in novel reproductive technologies: Prevention and treatment , 1993 .

[48]  S. Muasher Use of gonadotrophin-releasing hormone agonists in controlled ovarian hyperstimulation for in vitro fertilization. , 1992, Clinical therapeutics.

[49]  S. Oehninger,et al.  The gonadotropin-releasing hormone agonist stimulation test--a sensitive predictor of performance in the flare-up in vitro fertilization cycle. , 1991, Fertility and sterility.

[50]  B. Martin-Pont,et al.  Interest of growth hormone-releasing hormone administration for improvement of ovarian responsiveness to gonadotropins in poor responder women. , 1991, Fertility and sterility.

[51]  G. Jones,et al.  High‐dose follicle‐stimulating hormone stimulation at the onset of the menstrual cycle does not improve the in vitro fertilization outcome in low‐responder patients , 1991, Fertility and sterility.

[52]  R. Casper,et al.  Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization. , 1990, The Journal of clinical endocrinology and metabolism.

[53]  J E Garcia,et al.  Follicular phase gonadotropin-releasing hormone agonist and human gonadotropins: a better alternative for ovulation induction in in vitro fertilization. , 1990, Fertility and sterility.

[54]  J. Garcia,et al.  Prognostic value of the early serum estradiol response to leuprolide acetate in in vitro fertilization. , 1990, Fertility and sterility.

[55]  D. Meldrum,et al.  Routine pituitary suppression with leuprolide before ovarian stimulation for oocyte retrieval. , 1989, Fertility and sterility.

[56]  Z. Rosenwaks,et al.  The value of basal and/or stimulated serum gonadotropin levels in prediction of stimulation response and in vitro fertilization outcome. , 1988, Fertility and sterility.

[57]  Z. Rosenwaks,et al.  PROGNOSTIC ASSESSMENT OF FEMALE FECUNDITY , 1987, The Lancet.

[58]  A. Ferraretti,et al.  Serum luteinizing hormone during ovulation induction with human menopausal gonadotropin for in vitro fertilization in normally menstruating women. , 1983, Fertility and sterility.